LAJIN ENT (08172) announced that its board of directors wishes to inform shareholders and potential investors that the Listing Committee held a review hearing on October 21, 2025, regarding the decision made by the Listing Division. On November 3, 2025, the company received a letter from the Stock Exchange notifying that, after considering all written and oral submissions from the company and the Listing Division, the Committee determined that the company failed to maintain sufficient business operations and asset levels as required under GEM Listing Rule 17.26 to justify continued listing. Consequently, the Committee upheld the Listing Division's decision to suspend trading of the company's shares under GEM Listing Rule 9.04(3).

Under Chapter 4 of the GEM Listing Rules, the company has the right to request a review of the GEM Listing Committee's decision by the GEM Listing Review Committee. According to GEM Listing Rule 4.08(1), the company may submit such a request within seven business days after the issuance of the GEM Listing Committee's decision (i.e., by November 12, 2025). The company is currently seeking advice from external advisors and will consider whether to appeal the decision to the GEM Listing Review Committee.

Unless the company applies for a review, trading of its shares will be suspended upon the expiry of seven business days from the date of the GEM Listing Committee's decision (i.e., November 13, 2025). Pending a final decision on whether to appeal, the company's shares will continue to trade.